Algert Global LLC Purchases 31,710 Shares of TransMedics Group, Inc. $TMDX

Algert Global LLC lifted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 124.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,154 shares of the company's stock after purchasing an additional 31,710 shares during the period. Algert Global LLC owned about 0.17% of TransMedics Group worth $3,796,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Biondo Investment Advisors LLC bought a new stake in shares of TransMedics Group in the 2nd quarter valued at about $2,933,000. Emerald Investment Advisers LLC acquired a new stake in shares of TransMedics Group during the second quarter worth about $2,023,000. EP Wealth Advisors LLC acquired a new stake in TransMedics Group during the second quarter worth about $1,023,000. Keebeck Wealth Management acquired a new position in shares of TransMedics Group in the second quarter worth about $387,000. Finally, Allworth Financial LP purchased a new position in shares of TransMedics Group during the 2nd quarter valued at approximately $167,000. Institutional investors own 99.67% of the company's stock.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the business's stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the sale, the director owned 16,642 shares in the company, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company's stock.

TransMedics Group Stock Down 3.6%

Shares of NASDAQ:TMDX opened at $88.43 on Friday. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62. The company's fifty day moving average is $79.04 and its two-hundred day moving average is $93.89. TransMedics Group, Inc. has a 1-year low of $60.10 and a 1-year high of $156.00. The stock has a market capitalization of $3.06 billion, a price-to-earnings ratio of 22.73 and a beta of 1.90.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). The firm had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.TransMedics Group's revenue for the quarter was up 20.7% on a year-over-year basis. During the same quarter last year, the company posted $0.92 EPS. Equities analysts anticipate that TransMedics Group, Inc. will post 1.46 EPS for the current year.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several research reports. Zacks Research cut shares of TransMedics Group from a "hold" rating to a "strong sell" rating in a research note on Monday, July 6th. Needham & Company LLC cut their target price on shares of TransMedics Group from $142.00 to $106.00 and set a "buy" rating on the stock in a research note on Monday, August 3rd. Oppenheimer cut TransMedics Group from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 6th. Weiss Ratings downgraded TransMedics Group from a "hold (c)" rating to a "hold (c-)" rating in a report on Tuesday, July 28th. Finally, Stifel Nicolaus increased their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a "hold" rating in a research note on Thursday, June 18th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, TransMedics Group currently has an average rating of "Hold" and an average price target of $124.18.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source